4.1.4.2.1.3. anticholinergic drugs: adherence persistence. studies anticholinergic medication short term (twelve weeks). adherence clinical trials considered higher clinical practice . discontinuation rates high tolterodine twelve months, particularly high (68–95%) oxybutynin. two open-label extensions rcts fesoterodine8 mg showed adherence rates two years 49–84% . longitudinal disease analyser database study indicated increasing discontinuation rate, following treatment anticholinergics, 74.8% one year 87% three years . several rcts tried identify factors associated low/lower adherence persistence anticholinergics. identified as: low level efficacy (41.3%);adverse events (22.4%);cost (18.7%), although higher adherence rates observed drugs provided cost patients . factors associated poor adherence included: immediate release formulations (lower persistence compared er formulations);age (lower persistence among younger adults);unrealistic expectations treatment;gender distribution (better adherence/persistence female patients);ethnic group (african–americans ethnic minorities likely discontinue switch treatment).